早期口咽癌低体积颈部病变:放化疗与单纯放疗的队列研究
基于瑞典头颈癌登记的前瞻性队列研究,纳入1507例T1-2N1-2b口咽鳞癌患者,经倾向性评分匹配后比较放化疗与单纯放疗。
要点
- T1-2N1-2a口咽鳞癌单纯放疗与放化疗总生存和局部区域控制均无显著差异。
- T1-2N2b且≤70岁患者放化疗改善局部区域控制,但总生存未获益。
- T1-2N2b且>70岁患者放化疗无局部区域控制获益。
核心结论
- T1-2N1-2a口咽鳞癌单纯放疗是安全选择。
- T1-2N2b且≤70岁患者放化疗改善局部区域控制但不改善总生存。
研究设计与样本
- 基于瑞典头颈癌登记的前瞻性队列研究,利用医疗区域间放化疗使用差异。
- 采用1:1倾向性评分匹配平衡基线特征。
- 分别对T1-2N1-2a队列和T1-2N2b队列进行匹配和分析。
- 共纳入1507例T1-2N1-2b口咽鳞癌患者,匹配后N1-2a队列262例,N2b队列692例。
主要发现
- N1-2a队列局部区域控制放化疗与单纯放疗相似(HR 0.98,95%CI 0.34-2.78,p=0.98)。
- 局部区域控制差异由原发灶失败驱动,探索性分析提示T2N2b患者可能选择性获益于放化疗。
关键数值与推荐
- N1-2a定义为单个淋巴结<6 cm,N2b定义为多个淋巴结<6 cm(UICC第7版)。
- N1-2a队列局部区域控制HR 0.98(95%CI 0.34-2.78,p=0.98)。
临床怎么用
- T1-2N1-2a口咽鳞癌可考虑单纯放疗,避免不必要的化疗毒性。
- T1-2N2b且≤70岁患者可考虑放化疗以改善局部区域控制,但需权衡总生存无获益。
- T1-2N2b且>70岁患者放化疗无局部区域控制获益,倾向单纯放疗。
- T2N2b患者可能从放化疗中选择性获益,需个体化决策。
局限性
- 为基于登记数据的观察性队列研究,存在未测量混杂可能。
- 放化疗暴露基于医疗区域差异,非随机分配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The benefit of adding concurrent systemic therapy to definitive radiation therapy (RT) for patients with T1-2 oropharyngeal squamous cell carcinoma (OPSCC) and limited neck node involvement is uncertain. This study investigates whether chemotherapy (CRT) in patients with early-stage (T1-2) low-volume nodal disease (Union for International Cancer Control Seventh Edition N1-2b) improves overall survival (OS) compared with RT alone. METHODS AND MATERIALS: A cohort study of data from the prospective Swedish Head and Neck Cancer Register leveraged variation in receiving CRT based on the health care region. Propensity score matching (1:1) was applied to balance baseline characteristics between patients from regions favoring CRT and those receiving RT alone. OS and loco-regional control (LRC) were compared between groups using Kaplan-Meier analyses and Cox regression models. Separate matching and analyses were conducted for patients with T1-2N1-2a (cohort N1-2a, ie, single node < 6 cm) and T1-2N2b disease (cohort N2b, ie, multiple nodes < 6 cm). RESULTS: A total of 1507 patients with T1-2N1-2b OPSCC were included. After propensity score matching, cohort N1-2a consisted of 262 patients and cohort N2b of 692 patients. OS was similar between CRT and RT alone in both cohorts, with a hazard ratio (HR) of 1.57 (95% CI, 0.68-3.87; p = .17) for cohort N1-2a, and an HR of 0.95 (95% CI, 0.66-1.35; p = .77) for cohort N2b. LRC was also similar between CRT and RT in cohort N1-2a (HR, 0.98 [95% CI, 0.34-2.78]; p = .98). In cohort N2b, a statistical interaction (p < .001) was found with age, with a benefit of CRT for patients aged ≤70 years (HR, 0.30 [95% CI, 0.16-0.58]), but not for patients aged >70 years (HR, 1.48 [95% CI, 0.50-4.39]). The difference in LRC was driven by failures at the primary tumor site. Exploratory analyses suggested a selective benefit of CRT for patients with T2N2b. CONCLUSIONS: The results of this large, robust, national register suggest that RT alone is a safe treatment option for patients with T1-2N1-2a OPSCC. In patients with multiple neck nodes (N2b) aged ≤70 years, CRT improved LRC but not overall survival.
引用
- Adrian G, Falklind NR, McDowell L, et al. Chemoradiation Therapy Versus Radiation Therapy Alone in T1-2 Oropharyngeal Cancer With Low-Volume Neck Disease: A Population-Based Cohort Study Using the Swedish Head and Neck Cancer Register. Int J Radiat Oncol Biol Phys. 2025. PMID: 40848943. doi:10.1016/j.ijrobp.2025.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。